A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Mood disorders involve dysregulation in multiple neurotransmitter systems (serotonin, dopamine, norepinephrine), the hypothalamic-pituitary-adrenal (HPA) axis, and inflammatory markers. Genetic vulnerability interacts with environmental stress to shape these systems; critical periods in early development (trauma, attachment disruption) have lasting effects. Neuroimaging reveals structural and functional abnormalities in prefrontal and limbic regions, though causality and directionality remain unclear.
From your study of the serotonin and dopamine systems, you know these neurotransmitters play distinct roles in mood, motivation, and reward. The monoamine hypothesis of depression — the founding idea in this field — proposed that depression results from a deficiency of monoamine neurotransmitters (serotonin, dopamine, and norepinephrine) at synapses, and that antidepressants work by correcting this deficiency. This hypothesis was clinically productive: it predicted that drugs blocking monoamine reuptake or breakdown would have antidepressant effects, and they do. But the monoamine hypothesis is now understood to be incomplete. Antidepressants increase synaptic monoamines within hours, yet clinical improvement takes weeks — a delay that doesn't fit a simple deficiency story and points toward downstream adaptive changes (receptor desensitization, neuroplasticity, neurogenesis) as the actual therapeutic mechanism.
The HPA axis — hypothalamus, pituitary, adrenal gland — adds a second layer. Stress activates this axis, releasing cortisol. From your study of hormones and behavior, you know cortisol mobilizes energy and coordinates the stress response. In acute doses, this is adaptive. But in mood disorders, particularly melancholic depression, the HPA axis is chronically hyperactive: cortisol levels are elevated, the normal circadian rhythm of cortisol is blunted, and the feedback loop that shuts down cortisol secretion (via hippocampal glucocorticoid receptors) appears impaired. High, sustained cortisol damages hippocampal neurons, reduces hippocampal volume, and impairs the very feedback mechanisms that should terminate the stress response — a vicious cycle. This helps explain why early adverse experiences (trauma, neglect) increase lifetime risk for mood disorders: they sensitize the HPA axis during a critical developmental period, leaving it prone to overreaction for decades.
From your study of intracellular signaling and second messengers, you can appreciate that neurotransmitter dysregulation is not just about how much is released but about how downstream signaling cascades respond. One key pathway is the cAMP-PKA-CREB cascade: serotonin and norepinephrine receptors activate this pathway, which ultimately drives expression of brain-derived neurotrophic factor (BDNF). BDNF supports neuronal survival, synaptic plasticity, and hippocampal neurogenesis. In depression, BDNF expression in the hippocampus and prefrontal cortex is reduced; antidepressants restore it. This neuroplasticity hypothesis better accounts for the treatment delay than the monoamine hypothesis alone — it takes weeks for new synapses to form and new neurons to mature.
Neuroimaging studies have added anatomical specificity. Depression is consistently associated with reduced activity and volume in the prefrontal cortex — the region that regulates emotion through top-down inhibition of the amygdala — and hyperactivity in limbic regions including the amygdala and subgenual anterior cingulate cortex. This pattern fits a model where weakened prefrontal control fails to regulate an overactive threat/salience system, producing sustained negative affect, rumination, and impaired reward processing. Importantly, however, causality runs in both directions: depression may cause these structural changes (via stress-induced neuronal atrophy), but premorbid differences in these regions may also confer vulnerability. The neurobiological picture of mood disorders is a web of mutually reinforcing dysregulations — monoamines, HPA axis, inflammatory cytokines, and plasticity cascades — rather than a single broken mechanism.